Indeed, upon low doses of doxorubicin, which more closely recapitulate the clinical settings, it has been reported a protective role of p53, counteracting the late-onset cardiomyopathy and without activation of p53-dependent cell death cascades (65, 66). The gene discussed is TP53; the disease is cardiomyopathy.